Grant: Master's Award: Canada Graduate Scholarships
McGill University
$17,500.00
The Causality of Cholinergic Atrophy in Alzheimer's Disease
FY 2021-22
Summary
Alzheimers disease (AD), the leading cause of dementia, is characterized by the pathological accumulation of amyloid-β and tau proteins in key brain regions. These changes trigger early and progressive atrophy of basal forebrain cholinergic neurons that contribute to the onset of cognitive deficits. While the relationship between cholinergic loss and cognitive decline has been outlined, the extent to which amyloidosis or tau pathology contribute to this cholinergic loss remains unclear. Several studies support the theory that the primary cause of cholinergic loss in AD results from the cortical accumulation of tau. However, persuasive data from rodent models suggests that it is the accumulation of amyloid-β that provokes the greatest loss of cholinergic neurons. Furthermore, previous research suggests that nerve growth factor, critical for the survival of cholinergic neurons, is highly impaired in AD. The present study aims to (1) elucidate how the progression of AD-like tau accumulation contributes directly or indirectly, through deregulation of nerve growth factor metabolism to the degeneration of cholinergic neurons, and to (2) ascertain the extent to which amyloid-β contributes to tau-induced basal forebrain cholinergic deficits. To address these aims, the present study will compare cognitive decline and cholinergic loss in a rodent model displaying both amyloid-β and tau accumulation, with independent models of each pathology at key time points in the aging process. These comparisons will enable us to disentangle the independent and combined effects of these two AD hallmark pathologies. Given the increased incidence of AD among the Canadian population, this study reflects a critical step toward the identification of new biomarkers and/or therapeutics for AD.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
466956
Name
Semenak Amelia E
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
The Causality of Cholinergic Atrophy in Alzheimer's Disease
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Alzheimer'S Disease; Amyloid-ß; Cholinergic Loss; Cognitive Decline; Nerve Growth Factor; Rodent Models; Tau Protein
Abstract
Alzheimers disease (AD), the leading cause of dementia, is characterized by the pathological accumulation of amyloid-β and tau proteins in key brain regions. These changes trigger early and progressive atrophy of basal forebrain cholinergic neurons that contribute to the onset of cognitive deficits. While the relationship between cholinergic loss and cognitive decline has been outlined, the extent to which amyloidosis or tau pathology contribute to this cholinergic loss remains unclear. Several studies support the theory that the primary cause of cholinergic loss in AD results from the cortical accumulation of tau. However, persuasive data from rodent models suggests that it is the accumulation of amyloid-β that provokes the greatest loss of cholinergic neurons. Furthermore, previous research suggests that nerve growth factor, critical for the survival of cholinergic neurons, is highly impaired in AD. The present study aims to (1) elucidate how the progression of AD-like tau accumulation contributes directly or indirectly, through deregulation of nerve growth factor metabolism to the degeneration of cholinergic neurons, and to (2) ascertain the extent to which amyloid-β contributes to tau-induced basal forebrain cholinergic deficits. To address these aims, the present study will compare cognitive decline and cholinergic loss in a rodent model displaying both amyloid-β and tau accumulation, with independent models of each pathology at key time points in the aging process. These comparisons will enable us to disentangle the independent and combined effects of these two AD hallmark pathologies. Given the increased incidence of AD among the Canadian population, this study reflects a critical step toward the identification of new biomarkers and/or therapeutics for AD.
Competitiondate
202112
Approvedterm2
1 yr 0 mth
Pinamesdelim
Semenak, Amelia E
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~